Literature DB >> 14552882

Sensorimotor deficits in a unilateral intrastriatal 6-OHDA partial lesion model of Parkinson's disease in marmoset monkeys.

Andisheh Eslamboli1, Harry F Baker, Rosalind M Ridley, Lucy E Annett.   

Abstract

Animal studies investigating the efficacy of neurotrophic factors as treatments for Parkinson's disease (PD) ideally require partial dopamine (DA) lesion models. The intrastriatal 6-hydroxydopamine (6-OHDA) lesion model may be suitable for this purpose. Although this model has been well characterized in rodents, it has not previously been used in monkeys. The goal of the present study was to characterize the behavioral effects of unilateral injections of 6-OHDA in the basal ganglia of common marmoset monkeys (Callithrix jacchus). Cell counts from tyrosine hydroxylase immunochemistry 5 months postlesion revealed DA cell loss in the substantia nigra on the lesioned side to approximately 46% of relative to the unlesioned side. 6-OHDA lesioned monkeys showed a variety of behavioral deficits. Apomorphine induced rotation and simple sensorimotor measures (head position bias and PD disability rating score) were most affected by the lesion. The largest deficits were seen at 1 or 2 weeks postsurgery but had recovered by week 10. 6-OHDA lesioned monkeys took longer to complete a more complex sensorimotor staircase task. At 3.5 months postlesion, 6-OHDA monkeys also showed deficits on an object retrieval task designed to measure sensorimotor planning and skilled hand use. alpha-Methyl-p-tyrosine, a tyrosine hydroxylase inhibitor, reinstated those deficits which had undergone recovery in the lesioned animals and also exacerbated the deficits on the staircase task. This model has potential in assessing treatments for PD aimed at curtailing disease progression such as continuous delivery of neurotrophic factors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14552882     DOI: 10.1016/s0014-4886(03)00139-0

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  14 in total

1.  Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease.

Authors:  Andisheh Eslamboli; Biljana Georgievska; Rosalind M Ridley; Harry F Baker; Nicholas Muzyczka; Corinna Burger; Ronald J Mandel; Lucy Annett; Deniz Kirik
Journal:  J Neurosci       Date:  2005-01-26       Impact factor: 6.167

Review 2.  Non-human primate models of PD to test novel therapies.

Authors:  Marc Morissette; Thérèse Di Paolo
Journal:  J Neural Transm (Vienna)       Date:  2017-04-08       Impact factor: 3.575

3.  Sex differences in cognitive aging: a 4-year longitudinal study in marmosets.

Authors:  Emily S Rothwell; Kathryn P Workman; Dongwei Wang; Agnès Lacreuse
Journal:  Neurobiol Aging       Date:  2021-09-20       Impact factor: 4.673

Review 4.  Spatial neglect: clinical and neuroscience review: a wealth of information on the poverty of spatial attention.

Authors:  John C Adair; Anna M Barrett
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

5.  One-year change in cognitive flexibility and fine motor function in middle-aged male and female marmosets (Callithrix jacchus).

Authors:  Kathryn P Workman; Brianna Healey; Alyssa Carlotto; Agnès Lacreuse
Journal:  Am J Primatol       Date:  2018-10-03       Impact factor: 2.371

6.  Comparison of fetal mesencephalic grafts, AAV-delivered GDNF, and both combined in an MPTP-induced nonhuman primate Parkinson's model.

Authors:  D Eugene Redmond; Caleb R S McEntire; Joseph P Kingsbery; Csaba Leranth; John D Elsworth; Kimberly B Bjugstad; Robert H Roth; Richard J Samulski; John R Sladek
Journal:  Mol Ther       Date:  2013-08-05       Impact factor: 11.454

7.  Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice.

Authors:  K S Rommelfanger; G L Edwards; K G Freeman; L C Liles; G W Miller; D Weinshenker
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-16       Impact factor: 11.205

Review 8.  The 6-hydroxydopamine model of Parkinson's disease.

Authors:  Nicola Simola; Micaela Morelli; Anna R Carta
Journal:  Neurotox Res       Date:  2007-04       Impact factor: 3.911

Review 9.  Neurobehavioral development of common marmoset monkeys.

Authors:  Nancy Schultz-Darken; Katarina M Braun; Marina E Emborg
Journal:  Dev Psychobiol       Date:  2015-10-26       Impact factor: 3.038

10.  Systemic administration of 6-OHDA to rhesus monkeys upregulates HLA-DR expression in brain microvasculature.

Authors:  Valerie Joers; Scott Vermilyea; Kristine Dilley; Marina E Emborg
Journal:  J Inflamm Res       Date:  2014-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.